title: Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.
authors.affiliation: Thoracic Oncology Department, Siric OncoLille, University of Lille, CHU Lille, Lille, France. Alexis.CORTOT@chru-lille.fr.
authors.forename: Alexis B
authors.initials: AB
authors.lastname: Cortot
authors.affiliation: Thoracic Oncology Unit, CHU Grenoble, Grenoble, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Moro-Sibilot
authors.affiliation: AP-HP Hôpital Tenon, Chest Department-GRC-04 Theranoscan P&M Curie University Paris 6, Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D000068818:Cetuximab; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D000068818:Cetuximab